-
Study aim
-
Measurement of Crostin serum level after administration of 15mg Crocina
-
Design
-
Field trial, pragmatic, without blinding.
-
Settings and conduct
-
After obtaining informed consent, one crocin tablet made by Sami Saz company containing 15 mg of crocin will be administered orally during the trial to 5 healthy male volunteers. In the next step, blood sampling will be done at 0, 30, 60, 90, 120, 180 and 240 minutes after drug administration. blood serum will be separated with a centrifuge at 5000 rpm for 20 minutes.
In the next step, crostin is extracted from the serum and prepared for injection into the HPLC device. Analysis of crostin in blood will be done by HPLC.
The concentration curve will be drawn in terms of time, and the pharmacokinetic parameters including the maximum concentration, the time required to reach the maximum concentration, the area under the concentration graph in terms of time and the half-life time will be calculated.
-
Participants/Inclusion and exclusion criteria
-
Entry conditions: Patient willingness to participate in the study, Age above 18 years, No addiction to narcotics and sedatives and alcohol, No history of mental illness, not using anticoagulants, Absence of diabetes, Absence of underlying disease;
Non-entry conditions: Hemodynamic instability in participant, history of, Cardiopulmonary resuscitation in participant, past medical history of admission in the intensive care unit, abnormal liver tests ( AST، ALT، CBC ), abnormal kidney tests ( U/A، BUN، Cr )
-
Intervention groups
-
One tablet of Crocina (15 mg) made by Samisaz Company is given orally to healthy people who do not take any other medicine.
-
Main outcome variables
-
blood concentration of crocetin